Erica Pietroluongo MD,PhD

Oncologist | @UninaIT & @UChicago | Research on Thymic tumors, Lung Cancer, Neuroendocrine tumors.

[OncoDaily @oncodaily]

IASLC - What Does the Evolving Treatment Landscape Look Like for Thymic Epithelial Tumors?

@IASLC @StephenVLiu @nicogirardcurie @eripietroluongo

https://t.co/wScnngxwb2

[IASLC @IASLC]

#thymictumors are rare, making collaboration and specialized care essential.

Drs. @StephenVLiu, @nicogirardcurie & @eripietroluongo discuss #thymoma and thymic carcinoma, from diagnosis and staging to treatment, emerging therapies & research.

🎧 https://t.co/9oqPfBhX9g

@Itmig_society #ITMIG #ThoracicOncology #LungCancer #LungCancerConsidered

[IASLC @IASLC]

📰 New in ILCN: Drs. @eripietroluongo and @marinagarassino discuss the potential of deep learning models as a diagnostic tool for TET classification.

Read their insights now: https://t.co/vIV1x4kckk

#LCSM

[OncoDaily @oncodaily]

@StephenVLiu @nicogirardcurie @eripietroluongo @IASLC We would like to inform you that your post has been published on OncoDaily. Thank you for sharing!
https://t.co/oCt5TTbzoV

[Stephen V Liu, MD @StephenVLiu]

Fantastic discussion on updates for thymic cancers - thymoma and thymic carcinoma - with Dr. @nicogirardcurie and Dr. @eripietroluongo for the @IASLC podcast, Lung Cancer Considered. Stay tuned for this episode next week!

[Stephen V Liu, MD @StephenVLiu]

Join us in Washington, DC on Saturday, October 10 for #DCLung26 - a one-day, comprehensive, multidisciplinary, discussion-based lung cancer CME update! Dr. @marinagarassino will join to discuss state of the art treatment for fusion positive NSCLC!

https://t.co/EGGHrShgD7

[IASLC @IASLC]

🚨 Registration is now open for #LALCA26!

Join the global thoracic oncology community in São Paulo, Brazil, Nov. 12–14, 2026, for cutting-edge science, collaboration, and networking. Register early and save your spot today.

Register now: https://t.co/ax2ftUYECx

#IASLC #LungCancer #ThoracicOncology

[Chul Kim @chulkimMD]

Our paper on integrated molecular profiling of thymic epithelial tumors (TETs) is now out in @JCOPO_ASCO!

We analyzed 138 TET samples using whole-exome + whole-transcriptome sequencing to map the genomic landscape of thymomas and thymic carcinoma (TC).

https://t.co/NhXpL9Mny8

[Jordi Remon @JordiRemon]

More drugs ≠ better access.Despite a crowded NSCLC landscape,global inequities persist—driven by cost, fragmented regulation,and trial design. Our publication argues dose optimization could be a path toward more sustainable and equitable cancer care.
doi:10.1200/EDBK-26-517100

[Marina Garassino @marinagarassino]

Great team effort! @eripietroluongo @JamesDolezal and Matteo Sacco

[UChicago Medicine Comprehensive Cancer Center @UCCancerCenter]

Take a look at the latest research from @marinagarassino and colleagues showing how AI can help pathologists better classify a group of rare thymic tumors. @Annals_Oncology #CancerResearch
https://t.co/zYkg2YwqNa

[Stephen V Liu, MD @StephenVLiu]

Brilliant talk at #ITSD2026 from Prof. @veronesi_pietro: the economic unfeasability of personalized medicine in lung cancer. R&D costs are in the billions for a single drug. Value of drug development dependent on incidence, competitive market, probability of success. There is no economic incentive to develop a drug if incidence is too low - with our current models. The future? Changing our process. Use of in silico modeling and AI to change how we use and how we approve drugs.

[Stephen V Liu, MD @StephenVLiu]

Dr. @marinagarassino breaks down TROP2 ADCs at #ITCD2026, comparing and contrasting competing agents. Impressive outcomes in EGFR+ but will the future be broader? NMR as an emerging biomarkers?

[Stephen V Liu, MD @StephenVLiu]

Perspective @NatureCancer on GLP-1 medicines and cancer risk. Reducing obesity can reduce cancer risk, but beyond that, GLP-1 receptors are expressed on certain cancer cells - could be good or bad. Real world studies suggest lower incidence of some cancers. Overall, impact on inflammation, TME, and cancer risk needs closer study.

https://t.co/EJyp6lBgAa

[Stephen V Liu, MD @StephenVLiu]

Helpful updated review on immune-related disorders associated with thymic tumors from Dr. @eripietroluongo including myasthenia gravis, pure red cell aplasia, and Good's syndrome. Prognostic implications remain unclear.

https://t.co/r7Z17AVzBp

[JTO & JTO CRR @JTOonline]

Complete surgical resection remains the only potentially curative option for thymic epithelial tumors (TETs). Bang et al. found that perioperative pembrolizumab demonstrated promising rates of MPR, R0 resection, and long-term DFS in stage III to IV TETs. https://t.co/r0zSvfSmbC

[Stephen V Liu, MD @StephenVLiu]

Dr. @marinagarassino joins Milano virtually to discuss immunotherapy in NSCLC and walks through her approach to PS2, an important substance guided by many studies including IPSOS by @ProfSiowMingLee, important to note the cause of the poor PS.

[Stephen V Liu, MD @StephenVLiu]

Dr. @JordiRemon with a masterful talk on thymus epithelial tumors. Pathology review important, as many are misclassified. Adjuvant therapy needs definitive studies - ongoing now. Immunotherapy can be active but will also have greater toxicity than in lung cancer.

[Erica Pietroluongo MD,PhD @eripietroluongo]

New work from @UChicagoMed led by @GarassinoMarina 🇺🇸:
Routine H&E slides + deep learning enable reliable classification of thymic epithelial tumor subtypes, supporting digital pathology as a diagnostic aid in rare cancers.

Grateful for this outstanding team!

[Annals of Oncology @Annals_Oncology]

🆕Article in press: Deep learning discriminates thymic epithelial tumors histological subtypes using digital pathology

👉https://t.co/NfIFRiRGWW
@marinagarassino @eripietroluongo @matte_esse @AnnaDiLelloMD

[Stephen V Liu, MD @StephenVLiu]

Well written review from Dr. @eripietroluongo on thymic neuroendocrine tumors @JTOonline. Limited prospective data but activity seen with everolimus, cabozantinib, radionuclide therapy. Surgery, chemoradiation preferred when possible

https://t.co/PyYXjKehY1